Trial Profile
Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2022 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 31 Oct 2022 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 29 Oct 2021 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.